Hoth Therapeutics (HOTH)

• Market cap: $12.8M
• 1 day: -3.44%
• 5 days: -7.2%
• 1 month: 19.17%
• 3 months: -21.93%
• 6 months: -47.24%
• Year to date: -37.37%
• 1 year: -30.85%
• 5 years: -98.04%
• 10 years: -99.69%
• Sector: Healthcare
• Industry: Biotechnology

About: Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.

Employees: 3